

Newly Reported Substances: The following substances were reported to NFLIS-Drug for the first time between July 1, 2022, and September 30, 2022.

West

N-Boc norfentanyl

para-Fluoro acetyl fentanyl

South

N-Butylbutylone

ADB-5Br-BUTINACA

Midwest

MDMB-5Br-INACA

4'-Chloro deschloroalprazolam

Phenazepam

Northeast

Ethyl 4-ANPP

Bipiperidiny 4-ANPP

N-Cyclohexylbutylone

South, Midwest, and Northeast

Hexahydrocannabinol

South and Midwest

South and Northeast

Desalkylgizazepam




Snapshot of Drug Reports Received by NFLIS-Drug

The tables present the top five drug reports in each category received by NFLIS-Drug between July 1, 2022, and September 30, 2022.

Top 5 Reported Drugs	228,669	Synthetic Cannabinoids	1,205	Synthetic Cathinones	2,503
Methamphetamine	94,430	MDMB-4en-PINACA	439	Dipentylone	1,293
Fentanyl	43,061	ADB-BUTINACA	260	Eutylone	612
Cocaine	41,571	ADB-FUBIATA	67	alpha-PiHP	211
Cannabis/THC	38,194	FUB-AMB	38	<i>N</i> -Cyclohexylmethylone	87
Heroin	11,413	Fluoro-MDMB-PICA ¹	35	<i>N</i> -Propylbutylone	51

¹ Includes all positional and nonspecified isomers as reported by participating laboratories.

Upward Trends, by Date Submitted to Laboratory



Note: A reliable percentage for September could not be calculated because of the small proportion of expected total reports received by NFLIS at the time of analysis.

Data Disclaimer: Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in October 2022. Data in the Newly Reported Substances and Snapshot of Drug Reports Received by NFLIS-Drug sections include only drugs submitted to laboratories on or after July 1, 2021. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.deadiversion.usdoj.gov/nflisdata/docs/2k17NFLISQA.pdf>. NFLIS reports are available at <https://www.nflis.deadiversion.usdoj.gov/publicationsRedesign.xhtml>. Questions and comments: NFLIS@dea.gov

